-
Je něco špatně v tomto záznamu ?
Flavonolignans from silymarin modulate antibiotic resistance and virulence in Staphylococcus aureus
K. Holasová, B. Křížkovská, L. Hoang, S. Dobiasová, J. Lipov, T. Macek, V. Křen, K. Valentová, T. Ruml, J. Viktorová
Jazyk angličtina Země Francie
Typ dokumentu časopisecké články
NLK
Directory of Open Access Journals
od 2018
Elsevier Open Access Journals
od 2018-12-01
ROAD: Directory of Open Access Scholarly Resources
od 2002
- MeSH
- antibakteriální látky farmakologie MeSH
- antibiotická rezistence MeSH
- lidé MeSH
- silibinin farmakologie MeSH
- silymarin * chemie farmakologie MeSH
- stafylokokové infekce * MeSH
- Staphylococcus aureus MeSH
- virulence MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
Antibiotic resistance is currently a serious health problem. Since the discovery of new antibiotics no longer seems to be a sufficient tool in the fight against multidrug-resistant infections, adjuvant (combination) therapy is gaining in importance as well as reducing bacterial virulence. Silymarin is a complex of flavonoids and flavonolignans known for its broad spectrum of biological activities, including its ability to modulate drug resistance in cancer. This work aimed to test eleven, optically pure silymarin flavonolignans for their ability to reverse the multidrug resistance phenotype of Staphylococcus aureus and reduce its virulence. Silybin A, 2,3-dehydrosilybin B, and 2,3-dehydrosilybin AB completely reversed antibiotic resistance at concentrations of 20 μM or less. Both 2,3-dehydrosilybin B and AB decreased the antibiotic-induced gene expression of representative efflux pumps belonging to the major facilitator (MFS), multidrug and toxic compound extrusion (MATE), and ATP-binding cassette (ABC) families. 2,3-Dehydrosilybin B also inhibited ethidium bromide accumulation and efflux in a clinical isolate whose NorA and MdeA overproduction was induced by antibiotics. Most of the tested flavonolignans reduced cell-to-cell communication on a tetrahydrofuran-borate (autoinducer-2) basis, with isosilychristin leading the way followed by 2,3-dehydrosilybin A and AB, which halved communication at 10 μM. Anhydrosilychristin was the only compound that reduced communication based on acyl-homoserine lactone (autoinducer 1), with an IC50 of 4.8 μM. Except for isosilychristin and anhydrosilychristin, all of the flavonolignans inhibited S. aureus surface colonization, with 2,3-dehydrosilybin A being the most active (IC50 10.6 μM). In conclusion, the selected flavonolignans, particularly derivatives of 2,3-dehydrosilybin B, 2,3-dehydrosilybin AB, and silybin A are non-toxic modulators of S. aureus multidrug resistance and can decrease the virulence of the bacterium, which deserves further detailed research.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22018520
- 003
- CZ-PrNML
- 005
- 20220804134828.0
- 007
- ta
- 008
- 220720s2022 fr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.biopha.2022.112806 $2 doi
- 035 __
- $a (PubMed)35303568
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a fr
- 100 1_
- $a Holasová, Kateřina $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: rehorova@vscht.cz
- 245 10
- $a Flavonolignans from silymarin modulate antibiotic resistance and virulence in Staphylococcus aureus / $c K. Holasová, B. Křížkovská, L. Hoang, S. Dobiasová, J. Lipov, T. Macek, V. Křen, K. Valentová, T. Ruml, J. Viktorová
- 520 9_
- $a Antibiotic resistance is currently a serious health problem. Since the discovery of new antibiotics no longer seems to be a sufficient tool in the fight against multidrug-resistant infections, adjuvant (combination) therapy is gaining in importance as well as reducing bacterial virulence. Silymarin is a complex of flavonoids and flavonolignans known for its broad spectrum of biological activities, including its ability to modulate drug resistance in cancer. This work aimed to test eleven, optically pure silymarin flavonolignans for their ability to reverse the multidrug resistance phenotype of Staphylococcus aureus and reduce its virulence. Silybin A, 2,3-dehydrosilybin B, and 2,3-dehydrosilybin AB completely reversed antibiotic resistance at concentrations of 20 μM or less. Both 2,3-dehydrosilybin B and AB decreased the antibiotic-induced gene expression of representative efflux pumps belonging to the major facilitator (MFS), multidrug and toxic compound extrusion (MATE), and ATP-binding cassette (ABC) families. 2,3-Dehydrosilybin B also inhibited ethidium bromide accumulation and efflux in a clinical isolate whose NorA and MdeA overproduction was induced by antibiotics. Most of the tested flavonolignans reduced cell-to-cell communication on a tetrahydrofuran-borate (autoinducer-2) basis, with isosilychristin leading the way followed by 2,3-dehydrosilybin A and AB, which halved communication at 10 μM. Anhydrosilychristin was the only compound that reduced communication based on acyl-homoserine lactone (autoinducer 1), with an IC50 of 4.8 μM. Except for isosilychristin and anhydrosilychristin, all of the flavonolignans inhibited S. aureus surface colonization, with 2,3-dehydrosilybin A being the most active (IC50 10.6 μM). In conclusion, the selected flavonolignans, particularly derivatives of 2,3-dehydrosilybin B, 2,3-dehydrosilybin AB, and silybin A are non-toxic modulators of S. aureus multidrug resistance and can decrease the virulence of the bacterium, which deserves further detailed research.
- 650 _2
- $a antibakteriální látky $x farmakologie $7 D000900
- 650 _2
- $a antibiotická rezistence $7 D004352
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a silibinin $x farmakologie $7 D000077385
- 650 12
- $a silymarin $x chemie $x farmakologie $7 D012838
- 650 12
- $a stafylokokové infekce $7 D013203
- 650 _2
- $a Staphylococcus aureus $7 D013211
- 650 _2
- $a virulence $7 D014774
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Křížkovská, Bára $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: krizkova@vscht.cz
- 700 1_
- $a Hoang, Lan $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: hoangl@vscht.cz
- 700 1_
- $a Dobiasová, Simona $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: dobiasos@vscht.cz
- 700 1_
- $a Lipov, Jan $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: lipovj@vscht.cz
- 700 1_
- $a Macek, Tomáš $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: tomas.macek@vscht.cz
- 700 1_
- $a Křen, Vladimír $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ 142 20 Prague, Czech Republic. Electronic address: kren@biomed.cas.cz
- 700 1_
- $a Valentová, Kateřina $u Laboratory of Biotransformation, Institute of Microbiology of the Czech Academy of Sciences, Vídeňská 1083, CZ 142 20 Prague, Czech Republic. Electronic address: kata.valentova@email.cz
- 700 1_
- $a Ruml, Tomáš $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: rumlt@vscht.cz
- 700 1_
- $a Viktorová, Jitka $u Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology, Prague, Technická 3, Prague 166 28, Czech Republic. Electronic address: prokesoj@vscht.cz
- 773 0_
- $w MED00005486 $t Biomedicine & pharmacotherapy Biomedecine & pharmacotherapie $x 1950-6007 $g Roč. 149, č. - (2022), s. 112806
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35303568 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220720 $b ABA008
- 991 __
- $a 20220804134822 $b ABA008
- 999 __
- $a ok $b bmc $g 1822217 $s 1169763
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 149 $c - $d 112806 $e 20220315 $i 1950-6007 $m Biomedicine & pharmacotherapy $n Biomed Pharmacother $x MED00005486
- LZP __
- $a Pubmed-20220720